RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Overview

This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). These subjects will be compared to contemporary controls.

Full Title of Study: “An Open Label Phase 2, Study to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-vs-Host Disease Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 5, 2022

Detailed Description

This is an open-label, multi-center, single-arm study to evaluate six weekly doses of RGI-2001 in combination with standard of care treatment for the prevention of aGvHD in subjects following alloHSCT. The study will include a Safety Run-in Phase to assess the safety and tolerability of 6 weekly doses of RGI-2001 followed by an Expansion Phase in which the potential efficacy of 6 weekly doses of RGI-2001 in addition to standard of care for GvHD prophylaxis will be assessed. Comparison will be made to a contemporaneous control group.

Interventions

  • Drug: RGI-2001
    • Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
  • Drug: Standard of Care
    • Standard of care prophylaxis regimen will be administered according to institutional guidelines

Arms, Groups and Cohorts

  • Experimental: RGI-2001
    • Subjects will be administered RGI 2001 in combination with standard of care treatment

Clinical Trial Outcome Measures

Primary Measures

  • Grades II-IV aGVHD
    • Time Frame: Day 100 post-transplant
    • Acute GVHD will be graded and assessed within the first 100 days post-transplant

Secondary Measures

  • Grades II-IV aGVHD
    • Time Frame: Day 180 post-transplant
    • Acute GVHD will be graded and assessed within 180 days post-transplant
  • Non-relapse mortality (NRM) rates
    • Time Frame: Day 100, 6 months and 1 year post-transplant
    • The probability of mortality not preceded by relapse of the underlying malignancy will be estimated
  • Disease-free survival (DFS)
    • Time Frame: 6 months and 1 year post-transplant
    • The probability of survival without relapse of the underlying malignancy will be estimated
  • GvHD-free, relapse free survival (GRFS)
    • Time Frame: 6 months and 1 year post-transplant
    • The probability of survival without relapse of the underlying malignancy, without severe (grades 3-4) acute GVHD, and without chronic GVHD requiring systemic immunosuppression will be estimated
  • Overall survival (OS)
    • Time Frame: 6 months and 1 year post-transplant
    • The probability of survival will be estimated

Participating in This Clinical Trial

Inclusion Criteria

1. Ages ≥ 18 and ≤ 65 years of age 2. Has a hematologic malignancy which includes Acute myelogenous leukemia (AML), T or B cell acute lymphoblastic leukemia (ALL) Myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloproliferative disorder (MPD) including myeloid metaplasia and CML 3. Must have adequate organ function 4. Transplant Donor: Matched related donor or Unrelated donor 5. Is a candidate for anti-graft-vs-host-disease (GvHD) prophylaxis that includes a calcineurin inhibitor 6. Ability to understand and willingness to sign a written informed consent form 7. If female of childbearing potential, must have had a negative serum pregnancy test prior to enrollment and must have agreed to use a double barrier method of contraception for 30 days after RGI-2001 administration 8. If male, must be sterile or willing to use an approved method of contraception from the time of informed consent to 90 days after last dose of RGI-2001 administration Exclusion Criteria:

1. Has had any other prior organ transplantation 2. Planned procedure to deplete regulatory T cells from donor transplant materials 3. Planned reduced intensity conditioning 4. Has had prior treatment with anti-CD3, other T cell depleting antibodies, or anti-thymocyte globulin within 12 months prior to alloHSCT procedure 5. Has progressive underlying malignant disease including post-transplant lymphoproliferative disease 6. Has evidence of active central nervous system (CNS) disease including known brain or leptomeningeal disease (CT or MRI scan of the brain required only in case of clinical suspicion of CNS involvement) 7. Is female and pregnant or lactating 8. Has a documented history of uncontrolled autoimmune disease or on active treatment 9. History of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to receiving study drug

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Regimmune Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yi-Bin Chen, MD, Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.